AlphaLiquid® Profiling

​

The AlphaLiquid®100 test is a powerful tool in the cancer treatment. It enables the detection of biomarkers across 118 cancer-related genes via one blood test. This is crucial for predicting the efficacy or resistance of targeted therapies.

​

In a cancer patient's treatment journey, a simple blood draw with AlphaLiquid®100 can play a pivotal role. It supports the monitoring of how effective the treatment is and allows for a timely strategy shift when biomarkers indicating resistance appear. This seamless integration of advanced testing into the treatment process offers a more tailored and responsive approach to cancer care.

​

A Tumor-Agnostic Test

Tissue specimens are either from surgical resections or biopsies which may raise the risk of bleeding, and infection and further require recovery from the procedure. Genomic profiling of tissue samples provides a single point in space and time which is lacking the ability to reveal tumor heterogeneity and to test repeatedly to monitor the treatment efficacy. The risk of tissue biopsy is much higher for elderly patients and patients who are taking blood thinners. And the amount of specimen from one biopsy is not sufficient when several single driver gene tests are done separately (e.g. EGFR, ALK, ROS1, BRAF etc.).

AlphaLiquid® profiling test leverages liquid biopsy samples to detect tumor cell-derived circulation tumor DNA(ctDNA) that circulates in the bloodstream. A minimally invasive simple blood draw can avoid the inconvenience of surgical biopsy and detect ctDNA from bloodstream to overcome the heterogeneity in metastatic tumors which is not available for tissue biopsy in most cases.

AlphaLiquid®100 test is a CGP(Comprehensive Genomic Profiling, CGP) test detects variants across 118 cancer-related genes. The AlphaLiquid®100 is applicable for all solid tumors, including the leading cancer types like lung, gastric, colon, breast prostate, and also available for rare tumors including melanoma, sarcoma etc.

​